Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

This study tests a combination of two drugs — lenvatinib (a targeted therapy) and sintilimab (an immunotherapy) — for people with advanced liver cancer who previously received immunotherapy treatment but their cancer kept growing. **You may be eligible if...** - You are 18 or older - You have advanced liver cancer (hepatocellular carcinoma or intrahepatic bile duct cancer) that cannot be surgically removed - Your cancer progressed after receiving a PD-1 or PD-L1 immunotherapy drug - You have at least one measurable tumor on scans - You are in reasonably good physical health (ECOG score 0–2) - Your liver, kidney, and blood cell counts are within acceptable ranges **You may NOT be eligible if...** - You have never received prior immunotherapy for liver cancer - Your cancer is not measurable on imaging - You have uncontrolled bleeding, severe heart problems, or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.